Researchers from Atux Iskay LLC assessed whether reactivation of protein phosphatase 2A (PP2A) using a small-molecule PP2A activator, ATUX-1215, could counter TGF-β signaling in preclinical models of idiopathic pulmonary fibrosis (IPF).
Biosency SA's Bora Care remote monitoring solution can predict acute chronic obstructive pulmonary disease (COPD) exacerbations on average three days prior to hospitalization, according to initial results from an ongoing study. The results show that the technology can help prevent hospital admission and reduce the severity of acute exacerbation of COPD (AECOPD) leading to a better quality of life for COPD patients.
At the recent ATS meeting, Tavanta Therapeutics Inc. introduced TAVT-135, a cell-penetrating peptide (CPP) conjugate that acts as a chloride ion (Cl-) transporter. The product is currently being investigated for cystic fibrosis (CF), regardless of CF transmembrane conductance regulatory (CFTR) gene mutation status.
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive and chronic lung disease that causes scarring of the lung tissue and leads to an irreversible decline in lung function. Several studies have linked the p53 tumor suppressor gene to pulmonary fibrosis.
A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.
Research at Sensorium Therapeutics Inc. has led to the identification of deuterated alkaloids acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, depression, rheumatoid arthritis, stress and anxiety disorders.
Researchers at Academia Sinica, CSIC (Consejo Superior de Investigaciones Cientificas) and Universidad de Sevilla have divulged 5-aminohexahydro-6,7,8-trihydroxy-3h-oxazolo[3,4-a]pyridin-3-one derivatives acting as Toll-like receptor 4 (TLR4; CD284) antagonists or TLR4 agonists reported to be useful for the treatment of autoimmune disease, metabolic syndrome, asthma, inflammatory bowel disease, allergic rhinitis, nonalcoholic steatohepatitis, atherosclerosis and infections, among others, and also as vaccine adjuvants.
Researchers have compared the cellular responses driving allergic asthma to those in individuals with allergic rhinitis and conjunctivitis but no allergic response in the lungs. Asthma is “an umbrella term,” Josalyn Cho told BioWorld. But under that umbrella, the largest group of people are those whose asthma begins in childhood. And “those folks almost exclusively develop their asthma after they develop allergies.”
Chiesi Farmaceutici SpA has synthesized pyrrolidine derivatives acting as discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis and idiopathic pulmonary fibrosis (IPF).
RSS
